Northwell Health | Strategic Alliance Partners

Northwell Health Cancer Institute seamlessly integrates Northwell’s world-class hospitals, innovative treatments and leading cancer specialists of every kind. We’re dedicated to cancer prevention, screening, diagnosis, treatment, research and survivorship. Our disease-focused, multidisciplinary teams provide holistic care, treating patients’ cancer, as well as working with colleagues in disciplines throughout Northwell to treat any other existing medical conditions. Our experts provide comprehensive, compassionate care through innovative clinical trials, state-of-the-art medical and radiation oncology treatments and leading edge surgical techniques. More New Yorkers choose Northwell for cancer care than any other health system —which means you have access to the most experienced cancer fighters in the state.

Latest from Northwell Health

Dr. Rhodes on Evaluating the Unmet Needs of Elderly Patients in CLL

December 02, 2022

Video

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

November 23, 2021

Video

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Dr. Saif on the Rationale to Utilize PARP Inhibitors in BRCA+ Pancreatic Cancer

November 10, 2021

Video

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

Dr. Esteva on the Impact of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Breast Cancer

November 08, 2021

Video

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Breast Cancer Paradigm Moves Toward Less Morbid Treatments With Improved Risk Assessment and Imaging Strategies

November 03, 2021

Article

Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.

Dr. Esteva on Therapeutic Developments in HER2+ Breast Cancer

November 02, 2021

Video

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Dr. Baron on Contributing Factors for Developing Breast Cancer

November 02, 2021

Video

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

New Subcutaneous, Oral, and Intravenous Therapies Transform Treatment in Early-Stage HER2+ Breast Cancer

October 18, 2021

Article

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

NSCLC Paradigm Continues to Push Forward With Emerging Targets, but Predictive Biomarkers Are Limited

May 10, 2021

Article

Nagashree Seetharamu, MD, MBBS, discusses emerging targets in non–small cell lung cancer and the limitations of current biomarkers.

Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL

May 06, 2021

Video

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Dr. Barrientos on Selecting Between BCL-2 Inhibitors and BTK Inhibitors in CLL

May 03, 2021

Video

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Dr. Barrientos on the Shift Away From Chemoimmunotherapy in CLL

April 19, 2021

Video

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Saif Shares Key Treatment Considerations for Advanced Pancreatic Cancer

April 09, 2021

Article

Wasif Saif, MD, discusses factors to consider when choosing a frontline treatment strategy in pancreatic cancer, highlights the hunt for helpful biomarkers of response to available options, and offers sequencing suggestions.

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

April 09, 2021

Video

Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.

Immunotherapy Agents Demonstrate Groundbreaking Data in GI Cancers

April 05, 2021

Article

Lakshmi Rajdev, MD, discusses some of the key developments made with immunotherapy in GI cancers and the groundbreaking data that have recently read out to support their use.

Dr. Rajdev on the Efficacy of Pembrolizumab/Chemotherapy in Esophageal Cancer

April 02, 2021

Video

Lakshmi Rajdev, discusses the efficacy of pembrolizumab (Keytruda) plus chemotherapy in patients with esophageal cancer.

Dr. Philip on Non-Operative Treatment Advances in CRC

March 12, 2021

Video

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

ctDNA, Total Neoadjuvant Therapy, and TAS-102 Signal a Shift in CRC Management

March 12, 2021

Article

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Dr. Philip on the Emerging Role of ctDNA in CRC

March 09, 2021

Video

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Dr. Philip on the Efficacy of TAS-102 in mCRC

March 04, 2021

Video

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.